Lqttrx
1 known investors
Thryv Therapeutics is a clinical-stage biotechnology company developing selective inhibitors of serum glucocorticoid inducible kinase 1 (SGK1) for inherited cardiac arrhythmias such as Long QT Syndrome and acquired cardiometabolic diseases. Its lead compound, THRV-1268, is in a Phase 2/3 clinical study for Long QT Syndrome Type 2.